Residency · Residency · Endocrinology

Thyroid Emergencies - Thyroid Storm and Myxedema Coma

Thyroid Storm (Thyrotoxic Crisis)

Definition and Epidemiology

Thyroid storm represents a life-threatening exacerbation of thyrotoxicosis characterized by multisystem decompensation. It occurs in approximately 1 to 2% of hospitalized thyrotoxic patients and carries a mortality of 10 to 30% even with aggressive treatment. The critical distinction between thyroid storm and uncomplicated severe thyrotoxicosis lies not in the absolute thyroid hormone levels, which do not reliably differentiate the two conditions, but in the presence of systemic decompensation manifested by fever, altered mentation, and cardiovascular compromise. The diagnosis is fundamentally clinical, and treatment must not be delayed awaiting laboratory confirmation.

Precipitating Factors

Thyroid storm rarely occurs de novo and is almost always triggered by a precipitating event superimposed on existing thyrotoxicosis. Infection and sepsis are the most commonly identifiable triggers. Surgery, whether thyroid or non-thyroid, in an inadequately treated hyperthyroid patient is a classic precipitant. Other triggers include RAI therapy (through radiation thyroiditis releasing stored hormone), abrupt discontinuation of antithyroid drugs, iodinated contrast dye or amiodarone loading, trauma, diabetic ketoacidosis, stroke, pulmonary embolism, childbirth, preeclampsia, and excessive thyroid hormone ingestion.

Clinical Features

The clinical presentation of thyroid storm is characterized by extreme manifestations across multiple organ systems. Fever is a hallmark feature, typically exceeding 38.5 degrees Celsius (101.3 degrees Fahrenheit) and often reaching above 40 degrees Celsius (104 degrees Fahrenheit), accompanied by profuse diaphoresis. Cardiovascular decompensation includes tachycardia out of proportion to the fever (often exceeding 140 beats per minute), atrial fibrillation or flutter, wide pulse pressure, high-output heart failure, and, in advanced cases, cardiovascular collapse. Neurological manifestations range from agitation, delirium, and psychosis to seizures and coma, with the latter carrying an ominous prognosis. Gastrointestinal features include nausea, vomiting, diarrhea, abdominal pain, and jaundice, the last of which is a particularly poor prognostic sign reflecting hepatic dysfunction from either direct thyroid hormone toxicity or congestive hepatopathy. In the most severe cases, multisystem organ failure may develop, including hepatic failure, renal failure, disseminated intravascular coagulation, and rhabdomyolysis.

Burch-Wartofsky Point Scale (BWPS)

The Burch-Wartofsky Point Scale provides an objective scoring system for assessing the likelihood of thyroid storm, incorporating six parameters: temperature, central nervous system effects, gastrointestinal and hepatic dysfunction, heart rate, heart failure severity, and the presence of atrial fibrillation. A score of 45 or above is highly suggestive of thyroid storm, a score of 25 to 44 suggests impending storm, and a score below 25 makes storm unlikely. While widely used, the scale has not been prospectively validated, and clinical judgment must remain paramount in treatment decisions.

Japanese Thyroid Association (JTA) Diagnostic Criteria

The Japanese Thyroid Association has developed alternative diagnostic criteria that require the presence of thyrotoxicosis (elevated free T3 or free T4) plus at least one major clinical feature: CNS manifestation, fever of 38 degrees Celsius or above, tachycardia of 130 beats per minute or above, congestive heart failure, or GI/hepatic manifestation. A grade classification system (TS1, TS2, and definite) categorizes severity based on the combination and number of features present.

<image>A clinical scoring infographic for the Burch-Wartofsky Point Scale for thyroid storm. Create a scoring table with six parameters arranged vertically: (1) Temperature in both Fahrenheit and Celsius with points 0-30, (2) CNS effects from absent to seizures/coma with points 0-30, (3) GI-hepatic dysfunction from absent to jaundice with points 0-20, (4) Heart rate from <100 to >140 with points 0-25, (5) Heart failure from absent to pulmonary edema with points 0-15, (6) Atrial fibrillation absent vs present with points 0-10. Show total score ranges at bottom with color-coded zones: green (<25 unlikely), yellow (25-44 impending), red (≥45 highly suggestive). Include clinical vignette example with calculated score.</image>

Management of Thyroid Storm

Immediate Priorities (Simultaneous)

Management of thyroid storm requires simultaneous execution of multiple therapeutic strategies, with the patient admitted to an intensive care unit under continuous cardiac monitoring and hemodynamic support. Aggressive cooling measures are essential, using acetaminophen, cooling blankets, and ice packs. Aspirin must be avoided because it displaces T4 from thyroxine-binding globulin, acutely increasing free T4 levels and potentially worsening the storm. Intravenous fluids with dextrose-containing solutions address the hypermetabolic state that rapidly depletes glycogen stores. The precipitating cause must be identified and treated, with empiric antibiotics administered when infection is suspected.

Step 1: Block New Hormone Synthesis (ATDs)

PTU is the preferred antithyroid drug in thyroid storm, given as a 500 to 1000 mg loading dose (via oral, nasogastric, or rectal route), followed by 200 to 250 mg every 4 to 6 hours. PTU holds a unique advantage in this setting because it not only inhibits TPO-mediated hormone synthesis but also blocks peripheral T4-to-T3 conversion through D1 inhibition. Methimazole at 20 to 40 mg every 4 to 6 hours is an alternative when PTU is unavailable but lacks the peripheral conversion-blocking activity. Rectal administration through compounding may be necessary if the oral route is unavailable.

Step 2: Block Hormone Release (Iodine - Given at Least 1 Hour AFTER ATD)

Iodine preparations exploit the Wolff-Chaikoff effect to acutely block thyroid hormone release. Options include saturated solution of potassium iodide (SSKI) at 5 drops (250 mg) every 6 hours, Lugol solution at 10 drops every 8 hours, or sodium iodide at 500 to 1000 mg intravenously every 12 hours when the enteral route is unavailable. Oral cholecystographic agents such as iopanoic acid or sodium ipodate, which also inhibit D1, are effective but currently unavailable in many countries. Lithium carbonate at 300 mg every 6 to 8 hours serves as an alternative for iodine-allergic patients by blocking thyroid hormone release, with serum levels monitored during use.

The timing of iodine administration is critically important: iodine must be given at least 1 hour after the first ATD dose. If administered before the ATD has blocked organification, the iodine load provides fresh substrate for hormone synthesis, potentially worsening the thyrotoxicosis rather than ameliorating it.

Step 3: Block Peripheral Conversion and Adrenergic Effects

Propranolol at 60 to 80 mg orally every 4 to 6 hours (or 0.5 to 1 mg intravenously slowly every 15 minutes as needed) is the preferred beta-blocker because it inhibits D1-mediated T4-to-T3 conversion in addition to blocking adrenergic symptoms. Esmolol, administered as an intravenous infusion (250 to 500 mcg/kg loading dose followed by 50 to 100 mcg/kg/min), is valuable when the oral route is unavailable or when hemodynamic instability requires a short-acting, titratable agent.

Glucocorticoids play a multifaceted role in thyroid storm management. Hydrocortisone at 100 mg intravenously every 8 hours (or dexamethasone at 2 mg intravenously every 6 hours) serves three purposes: blocking T4-to-T3 conversion, treating relative adrenal insufficiency resulting from accelerated cortisol metabolism in the hypermetabolic state, and providing potential anti-inflammatory effects. Dexamethasone is preferred when concurrent diagnostic evaluation for adrenal insufficiency is planned, as it does not interfere with the cosyntropin stimulation test.

Step 4: Remove Circulating Hormone (Refractory Cases)

For cases refractory to standard medical therapy, additional measures to remove circulating thyroid hormones may be employed. Cholestyramine at 4 grams orally four times daily binds thyroid hormones undergoing enterohepatic circulation and serves as a useful adjunct. Plasmapheresis or plasma exchange directly removes circulating T4, T3, and antibodies, providing a temporizing measure when medical therapy fails, though its effect is temporary, lasting only hours to days. Emergency thyroidectomy may be considered in truly refractory storm after maximal medical stabilization, representing a high-risk but potentially life-saving intervention.

Monitoring and Outcomes

Continuous cardiac monitoring is essential throughout the treatment course. Serial thyroid function tests are obtained but should be interpreted with the understanding that biochemical improvement may lag behind clinical improvement. Clinical improvement is expected within 12 to 24 hours of aggressive multimodal therapy, with full biochemical normalization occurring over days to weeks. Mortality remains 10 to 30% even with optimal treatment, with higher rates associated with delayed diagnosis, advanced age, multiorgan failure, and jaundice. After resolution of the acute crisis, definitive therapy for the underlying hyperthyroidism (RAI or surgery) must be planned once the patient has stabilized.

Myxedema Coma

Definition and Epidemiology

Myxedema coma represents the most severe, decompensated form of hypothyroidism, characterized by altered mental status and hypothermia in the setting of profound thyroid hormone deficiency. The term is somewhat of a misnomer, as frank coma is present in only a minority of patients; altered sensorium ranging from lethargy and obtundation to confusion is more typical. Myxedema coma is extremely rare, with an estimated incidence of 0.22 per million per year, but carries a devastating mortality rate of 30 to 60%. It occurs most commonly in elderly women during winter months, with cold exposure serving as a common environmental trigger. Most cases develop in patients with known hypothyroidism who have discontinued levothyroxine or in individuals with undiagnosed, longstanding hypothyroidism.

Precipitating Factors

As with thyroid storm, myxedema coma is nearly always triggered by a precipitating event. Infection, particularly pneumonia, urinary tract infection, or sepsis, is the most common precipitant. Cold exposure and hypothermia, medications with sedative or thyroid-suppressive properties (sedatives, opioids, anesthetics, amiodarone, lithium), stroke, myocardial infarction, trauma, surgery, gastrointestinal bleeding, metabolic derangements, discontinuation of thyroid hormone replacement, and coexistent adrenal crisis all represent recognized triggers.

Clinical Features

The clinical picture of myxedema coma reflects the profound depression of virtually all organ systems. Hypothermia is the defining feature, with core temperatures typically below 35.5 degrees Celsius (95.9 degrees Fahrenheit) and sometimes below 30 degrees Celsius in severe cases. Critically, the absence of fever does not exclude concurrent infection, as the febrile response is blunted in severe hypothyroidism.

Neurological manifestations include lethargy, obtundation, confusion, psychosis, coma, seizures, and decreased deep tendon reflexes with the characteristically prolonged relaxation phase. Cardiovascular findings include bradycardia, hypotension, low cardiac output, pericardial effusion (with cardiac tamponade being rare but possible), prolonged QT interval, and torsades de pointes. Respiratory compromise is often prominent, with hypoventilation from both central respiratory drive depression and respiratory muscle weakness, leading to hypercapnia and hypoxemia. Pleural effusions may further compromise respiratory function, and many patients require mechanical ventilation. Gastrointestinal manifestations include paralytic ileus, megacolon, gastric atony, and GI bleeding. Renal dysfunction with decreased GFR, hyponatremia from impaired free water excretion, and oliguria are common. The generalized non-pitting edema of myxedema, dry cool skin, periorbital edema, and macroglossia are present. Hematologic abnormalities may include coagulopathy, anemia, and occasionally DIC.

Laboratory Findings

Laboratory evaluation reveals markedly elevated TSH in primary hypothyroidism or low/normal TSH in central hypothyroidism, with very low free T4 and T3. Hyponatremia, present in approximately 50% of cases, is dilutional in nature. Hypoglycemia reflects impaired gluconeogenesis. Elevated creatine kinase may suggest rhabdomyolysis. Hypercapnia and respiratory acidosis reflect the hypoventilation. Elevated lactate indicates tissue hypoperfusion. The CBC may show anemia and possible leukopenia.

<image>A clinical management protocol diagram for myxedema coma organized as a systematic treatment approach. Show a patient figure in ICU setting with monitors. Arranged around the figure, show simultaneous interventions: (1) Airway management with intubation for hypoventilation, (2) IV levothyroxine loading dose 200-400 mcg followed by 50-100 mcg daily with an alternative box showing IV T3 5-20 mcg then 2.5-10 mcg q8h, (3) IV hydrocortisone 100 mg q8h stress dosing with note "GIVE BEFORE or WITH thyroid hormone", (4) Passive rewarming with blankets (avoid active rewarming which can cause vasodilation and shock), (5) IV fluids with dextrose for hypoglycemia and hyponatremia management, (6) Identify and treat precipitant (infection, medications). Include monitoring parameters: core temperature, cardiac telemetry, serial sodium, cortisol levels. Use ICU-style medical illustration with color-coded intervention boxes.</image>

Management of Myxedema Coma

General Supportive Measures

All patients require ICU admission with continuous monitoring. Airway management with intubation is frequently necessary for hypoventilation and airway protection. Rewarming must be passive, using blankets only. Active external rewarming is specifically contraindicated because it causes peripheral vasodilation, which, in the setting of an myxedematous cardiovascular system that cannot compensate with increased cardiac output, leads to circulatory collapse. Intravenous fluids with isotonic saline are administered, avoiding free water given the risk of worsening hyponatremia, and dextrose-containing solutions address hypoglycemia. Vasopressors may be required for refractory hypotension, though the hemodynamic response may be blunted until thyroid hormone takes effect. Empiric antibiotics should be administered given that infection is the most common precipitant and the febrile response is blunted.

Glucocorticoid Replacement (Give BEFORE or WITH Thyroid Hormone)

Hydrocortisone at 100 mg intravenously as a bolus, followed by 50 to 100 mg intravenously every 8 hours, must be given before or simultaneously with thyroid hormone replacement. The rationale is threefold: coexistent adrenal insufficiency, whether from pituitary disease or autoimmune polyglandular syndrome, may be present and would be unmasked by thyroid hormone replacement; thyroid hormones increase cortisol clearance, potentially precipitating adrenal crisis; and the severe physiological stress of myxedema coma itself demands adequate glucocorticoid support. Cortisol and ACTH levels should ideally be obtained before or shortly after initiating steroids, and the glucocorticoid taper is guided by subsequent testing.

Thyroid Hormone Replacement

IV Levothyroxine (T4)

Intravenous levothyroxine is administered as a loading dose of 200 to 400 mcg (using the lower end for elderly patients, small patients, and those with cardiac disease), followed by maintenance dosing of 50 to 100 mcg intravenously daily until oral intake is possible. The loading dose is necessary because the depleted body pool of T4, combined with the hormone's long half-life, means that achieving therapeutic levels rapidly requires front-loading.

IV Liothyronine (T3)

Intravenous liothyronine at a 5 to 20 mcg loading dose followed by 2.5 to 10 mcg intravenously every 8 hours provides faster onset of action (hours versus days for T4) and addresses the impaired T4-to-T3 conversion that accompanies critical illness due to reduced D1 and D2 deiodinase activity. However, T3 carries a risk of cardiac arrhythmias and myocardial ischemia, particularly in elderly patients, and high doses should be avoided in those with cardiac disease. The choice between T4 alone versus combination T4/T3 therapy remains controversial, as no randomized controlled trials have compared the approaches.

Approach Strategies (No Consensus)

A conservative approach using T4 alone (200 to 300 mcg loading followed by 50 to 100 mcg daily) is preferred in elderly patients and those with cardiac disease. An aggressive approach combining T4 and T3 (T4 200 to 400 mcg loading plus T3 5 to 10 mcg every 8 hours) is favored in younger patients with severe presentations or when there is no clinical improvement within 24 to 48 hours on T4 alone. Transition to oral therapy occurs when GI function recovers, with the oral T4 dose set at approximately 80% of the intravenous dose.

Monitoring

Core temperature should be monitored continuously using rectal or esophageal probes, with a goal of gradual rewarming at approximately 0.5 degrees Celsius per hour. Continuous cardiac monitoring is essential given the risk of arrhythmia during thyroid hormone replacement. Serial serum sodium measurements are critical, as overly rapid correction of chronic hyponatremia risks osmotic demyelination. Serial cortisol levels guide the glucocorticoid taper. Thyroid function tests are obtained but clinical improvement may precede biochemical normalization, and T4/T3 levels alone should not solely guide therapy.

Prognosis

Mortality remains 30 to 60% despite treatment, underscoring the critical importance of early recognition and aggressive therapy. Poor prognostic factors include advanced age, persistent hypothermia despite treatment, bradycardia unresponsive to therapy, sepsis, multiorgan failure, Glasgow Coma Scale below 8 at presentation, and high APACHE II scores.

Amiodarone-Induced Thyroid Dysfunction

Background

Amiodarone's effects on thyroid function are a consequence of its extraordinarily high iodine content: the drug is 37% iodine by weight, and each 200 mg tablet delivers approximately 75 mg of organic iodine, which is 50 to 100 times the recommended daily intake. Amiodarone's extremely long half-life of 40 to 55 days means that iodine excess persists for months after discontinuation. Beyond its iodine load, amiodarone directly inhibits D1 and D2 deiodinases and exerts direct cytotoxic effects on thyroid follicular cells. Thyroid dysfunction develops in 15 to 20% of amiodarone-treated patients.

Amiodarone-Induced Hypothyroidism (AIH)

Amiodarone-induced hypothyroidism is more common in iodine-sufficient regions, reflecting the Wolff-Chaikoff effect in susceptible thyroid glands. It typically occurs in patients with underlying Hashimoto thyroiditis, as evidenced by positive TPO antibodies. Management is straightforward: levothyroxine replacement is initiated while amiodarone can be continued if the cardiac indication warrants it.

Amiodarone-Induced Thyrotoxicosis (AIT)

Amiodarone-induced thyrotoxicosis is more clinically challenging and is classified into two types. Type 1 AIT represents iodine-induced hyperthyroidism in patients with underlying thyroid disease (Graves disease or toxic nodules), occurring through the Jod-Basedow phenomenon. Clinical clues include pre-existing thyroid disease or goiter, elevated or relatively preserved RAIU (though it may be normal due to the iodine load), and increased vascularity on color Doppler ultrasonography. Treatment consists of ATDs, often at higher doses than usual due to the competing iodine load, with perchlorate (where available) considered to block further iodine uptake.

Type 2 AIT is a destructive thyroiditis caused by the direct cytotoxic effects of amiodarone on normal thyroid glands. Clinical features include the absence of underlying thyroid disease, absent or very low RAIU, absent color Doppler flow (an avascular gland), and elevated IL-6. Treatment relies on glucocorticoids, typically prednisone 40 to 60 mg daily tapered over 2 to 3 months, and the condition is self-limited. In practice, mixed or indeterminate forms with features of both types are the most common presentation, and combination therapy with ATDs plus glucocorticoids is often necessary.

The decision to discontinue amiodarone requires careful risk-benefit assessment, as the cardiac indication may be life-threatening, and discontinuation is not always necessary for type 2 AIT. Emergency thyroidectomy may be required for life-threatening AIT refractory to medical therapy, particularly in patients with decompensated heart failure.

Key Clinical Pearls

• In thyroid storm, PTU is preferred over methimazole because it also blocks peripheral T4-to-T3 conversion; iodine must be given at least 1 hour AFTER the first ATD dose to prevent Jod-Basedow worsening
• Aspirin should be AVOIDED in thyroid storm because it displaces T4 from binding proteins, acutely increasing free T4 levels; use acetaminophen for fever
• Myxedema coma is a clinical diagnosis; do not delay treatment waiting for lab results; empiric IV hydrocortisone should be given BEFORE or simultaneously with thyroid hormone
• Active external rewarming in myxedema coma can cause fatal cardiovascular collapse from peripheral vasodilation; use passive rewarming (blankets) only
• The Burch-Wartofsky score ≥45 is suggestive of thyroid storm, but clinical judgment supersedes the score; treatment should not be withheld in a patient with clinical features of storm and a borderline score
• Amiodarone-induced thyrotoxicosis type 2 responds to glucocorticoids, NOT antithyroid drugs; distinguishing type 1 from type 2 (or mixed) is critical for appropriate treatment but often challenging in practice

References

1. Burch HB, Wartofsky L. "Life-Threatening Thyrotoxicosis: Thyroid Storm." Endocrinol Metab Clin North Am. 1993;22(2):263-277.
2. Akamizu T, et al. "Diagnostic Criteria, Clinical Features, and Incidence of Thyroid Storm Based on Nationwide Surveys." Thyroid. 2012;22(7):661-679.
3. Jonklaas J, et al. "Guidelines for the Treatment of Hypothyroidism." Thyroid. 2014;24(12):1670-1751.
4. Ross DS, et al. "2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism." Thyroid. 2016;26(10):1343-1421.
5. Bartalena L, et al. "Diagnosis and Management of Amiodarone-Induced Thyrotoxicosis." J Clin Endocrinol Metab. 2018;103(4):1-10.

Read this lecture as Markdown